Viking Therapeutics (VKTX) Cash from Investing Activities (2015 - 2026)

Viking Therapeutics has disclosed Cash from Investing Activities across 12 years of filings, most recently posting $54.2 million for Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at $54.2 million, down 14.32% year-over-year; the trailing twelve-month figure through Mar 2026 was $332.3 million (up 1195.76% YoY), and the FY2025 annual result was $341.4 million, up 161.69% from the prior year.
• Cash from Investing Activities came in at $54.2 million for Q1 2026 at Viking Therapeutics, down from $75.6 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $160.0 million in Q3 2025 to a low of -$459.8 million in Q1 2024.
• The 5-year median for Cash from Investing Activities is $19.0 million (2022), against an average of -$16.6 million.
• Across the five-year window, Cash from Investing Activities sank 21018.65% in 2024 and surged 1048.42% in 2025, its largest moves.
• Viking Therapeutics' Cash from Investing Activities stood at $7.3 million in 2022, then jumped by 392.19% to $35.7 million in 2023, then plunged by 81.57% to $6.6 million in 2024, then soared by 1048.42% to $75.6 million in 2025, then declined by 28.33% to $54.2 million in 2026.
• The last three Cash from Investing Activities figures came in at $54.2 million (Q1 2026), $75.6 million (Q4 2025), and $160.0 million (Q3 2025), per Business Quant data.